Utilization Patterns of IV Iron and Erythropoiesis Stimulating Agents in Anemic Chronic Kidney Disease Patients: A Multihospital Study
Intravenous (IV) iron and Erythropoiesis Stimulating Agents (ESAs) are recommended for anemia management in chronic kidney disease (CKD). This retrospective cohort study analyzed utilization patterns of IV iron and ESA in patients over 18 years of age admitted to University Health System Hospitals w...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Anemia |
| Online Access: | http://dx.doi.org/10.1155/2012/248430 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832566210049343488 |
|---|---|
| author | Avani D. Joshi David A. Holdford Donald F. Brophy Spencer E. Harpe Darcy Mays Todd W. B. Gehr |
| author_facet | Avani D. Joshi David A. Holdford Donald F. Brophy Spencer E. Harpe Darcy Mays Todd W. B. Gehr |
| author_sort | Avani D. Joshi |
| collection | DOAJ |
| description | Intravenous (IV) iron and Erythropoiesis Stimulating Agents (ESAs) are recommended for anemia management in chronic kidney disease (CKD). This retrospective cohort study analyzed utilization patterns of IV iron and ESA in patients over 18 years of age admitted to University Health System Hospitals with a primary or secondary diagnosis of CKD between January 1, 2006 to December 31, 2008. A clustered binomial logistic regression using the GEE methodology was used to identify predictors of IV iron utilization. Only 8% (n = 6678) of CKD patients on ESA therapy received IV iron supplementation in university hospitals. Those receiving iron used significantly less amounts of ESAs. Patient demographics (age, race, primary payer), patient clinical conditions (admission status, severity of illness, dialysis status), and physician specialty were identified as predictors of IV iron use in CKD patients. Use of IV iron with ESAs was low despite recommendations from consensus guidelines. The low treatment rate of IV iron represents a gap in treatment practices and signals an opportunity for healthcare improvement in CKD anemic patients. |
| format | Article |
| id | doaj-art-65496a8238d24ec090478566e7900cc1 |
| institution | Kabale University |
| issn | 2090-1267 2090-1275 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Anemia |
| spelling | doaj-art-65496a8238d24ec090478566e7900cc12025-02-03T01:04:53ZengWileyAnemia2090-12672090-12752012-01-01201210.1155/2012/248430248430Utilization Patterns of IV Iron and Erythropoiesis Stimulating Agents in Anemic Chronic Kidney Disease Patients: A Multihospital StudyAvani D. Joshi0David A. Holdford1Donald F. Brophy2Spencer E. Harpe3Darcy Mays4Todd W. B. Gehr5Global Heath Economics and Outcomes Research, Abbott Laboratories, North Chicago, IL 60064, USADepartment of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University School of Pharmacy, P.O. Box 980533, 1112 East Clay Street, Richmond, VA 23298, USADepartment of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University School of Pharmacy, P.O. Box 980533, 1112 East Clay Street, Richmond, VA 23298, USADepartment of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University School of Pharmacy, P.O. Box 980533, 1112 East Clay Street, Richmond, VA 23298, USAStatistical Sciences & Operations Research, Virginia Commonwealth University, P.O. Box 843083, Richmond, VA 23284, USAVCU Internal Medicine, Division of Nephrology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23298, USAIntravenous (IV) iron and Erythropoiesis Stimulating Agents (ESAs) are recommended for anemia management in chronic kidney disease (CKD). This retrospective cohort study analyzed utilization patterns of IV iron and ESA in patients over 18 years of age admitted to University Health System Hospitals with a primary or secondary diagnosis of CKD between January 1, 2006 to December 31, 2008. A clustered binomial logistic regression using the GEE methodology was used to identify predictors of IV iron utilization. Only 8% (n = 6678) of CKD patients on ESA therapy received IV iron supplementation in university hospitals. Those receiving iron used significantly less amounts of ESAs. Patient demographics (age, race, primary payer), patient clinical conditions (admission status, severity of illness, dialysis status), and physician specialty were identified as predictors of IV iron use in CKD patients. Use of IV iron with ESAs was low despite recommendations from consensus guidelines. The low treatment rate of IV iron represents a gap in treatment practices and signals an opportunity for healthcare improvement in CKD anemic patients.http://dx.doi.org/10.1155/2012/248430 |
| spellingShingle | Avani D. Joshi David A. Holdford Donald F. Brophy Spencer E. Harpe Darcy Mays Todd W. B. Gehr Utilization Patterns of IV Iron and Erythropoiesis Stimulating Agents in Anemic Chronic Kidney Disease Patients: A Multihospital Study Anemia |
| title | Utilization Patterns of IV Iron and Erythropoiesis Stimulating Agents in Anemic Chronic Kidney Disease Patients: A Multihospital Study |
| title_full | Utilization Patterns of IV Iron and Erythropoiesis Stimulating Agents in Anemic Chronic Kidney Disease Patients: A Multihospital Study |
| title_fullStr | Utilization Patterns of IV Iron and Erythropoiesis Stimulating Agents in Anemic Chronic Kidney Disease Patients: A Multihospital Study |
| title_full_unstemmed | Utilization Patterns of IV Iron and Erythropoiesis Stimulating Agents in Anemic Chronic Kidney Disease Patients: A Multihospital Study |
| title_short | Utilization Patterns of IV Iron and Erythropoiesis Stimulating Agents in Anemic Chronic Kidney Disease Patients: A Multihospital Study |
| title_sort | utilization patterns of iv iron and erythropoiesis stimulating agents in anemic chronic kidney disease patients a multihospital study |
| url | http://dx.doi.org/10.1155/2012/248430 |
| work_keys_str_mv | AT avanidjoshi utilizationpatternsofivironanderythropoiesisstimulatingagentsinanemicchronickidneydiseasepatientsamultihospitalstudy AT davidaholdford utilizationpatternsofivironanderythropoiesisstimulatingagentsinanemicchronickidneydiseasepatientsamultihospitalstudy AT donaldfbrophy utilizationpatternsofivironanderythropoiesisstimulatingagentsinanemicchronickidneydiseasepatientsamultihospitalstudy AT spencereharpe utilizationpatternsofivironanderythropoiesisstimulatingagentsinanemicchronickidneydiseasepatientsamultihospitalstudy AT darcymays utilizationpatternsofivironanderythropoiesisstimulatingagentsinanemicchronickidneydiseasepatientsamultihospitalstudy AT toddwbgehr utilizationpatternsofivironanderythropoiesisstimulatingagentsinanemicchronickidneydiseasepatientsamultihospitalstudy |